Kim So Jeong, Kim Na Young, Chung Soo Jie, Kim Changhwan, Choi Jeong-Hee, Hyun In Gyu, Yeo Yohwan, Park Ji Young, Jang Seung Hun, Kim Taehee, Sim Yun Su, Lee Chang Youl, Kim Junghyun
Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Republic of Korea.
Department of Family Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Republic of Korea.
J Thorac Dis. 2025 Aug 31;17(8):5843-5855. doi: 10.21037/jtd-2025-489. Epub 2025 Aug 27.
Concurrent chemoradiotherapy (CCRT) is the standard treatment for patients with unresectable stage III non-small-cell lung cancer (NSCLC) and good performance status. However, there is no consensus regarding the treatment of older patients with stage III NSCLC. Therefore, this study aimed to investigate treatment outcomes and safety of CCRT in older patients with unresectable stage III NSCLC compared with those in younger patients.
We retrospectively examined all patients with unresectable stage III NSCLC treated with CCRT between 2012 and 2023 at four Korean hospitals. Progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were compared between patients aged ≥70 years (older) and those aged <70 years (younger). We also analyzed data for age cutoffs of 60, 65, and 75 years.
Among 131 participants, 47 were classified as older patients and 84 as younger patients. Baseline characteristics, including Eastern Cooperative Oncology Group performance status and comorbidities, were mostly similar. In multivariable-adjusted models, older and younger patients had similar PFS [adjusted hazard ratio (aHR), 1.45; 95% confidence interval (CI): 0.85-2.48]; the median PFS in older and younger patients was 9.9 and 12.9 months, respectively (P=0.94). However, in multivariable-adjusted models, older patients had worse OS (aHR, 2.33; 95% CI: 1.27-4.27); the median OS in older and younger patients was 24.1 and 27.2 months, respectively (P=0.36). AEs of any grade and those of grade ≥3 were not significantly different between older and younger groups.
Among patients with unresectable stage III NSCLC undergoing CCRT, older patients aged ≥70 years had similar PFS and AE rates compared with those aged <70 years. However, OS was worse in older patients. Considering age as a crucial factor in CCRT outcomes, efforts should be made to provide a more meticulous and careful approach for older patients.
同步放化疗(CCRT)是不可切除的III期非小细胞肺癌(NSCLC)且体能状态良好患者的标准治疗方法。然而,对于老年III期NSCLC患者的治疗尚无共识。因此,本研究旨在探讨不可切除的III期NSCLC老年患者与年轻患者相比CCRT的治疗效果和安全性。
我们回顾性研究了2012年至2023年期间在韩国四家医院接受CCRT治疗的所有不可切除的III期NSCLC患者。比较了年龄≥70岁(老年)和年龄<70岁(年轻)患者的无进展生存期(PFS)、总生存期(OS)和不良事件(AE)。我们还分析了年龄临界值为60、65和75岁时的数据。
在131名参与者中,47名被归类为老年患者,84名被归类为年轻患者。包括东部肿瘤协作组体能状态和合并症在内的基线特征大多相似。在多变量调整模型中,老年和年轻患者的PFS相似[调整后风险比(aHR),1.45;95%置信区间(CI):0.85 - 2.48];老年和年轻患者的中位PFS分别为9.9个月和12.9个月(P = 0.94)。然而,在多变量调整模型中,老年患者的OS较差(aHR,2.33;95% CI:1.27 - 4.27);老年和年轻患者的中位OS分别为24.1个月和27.2个月(P = 0.36)。老年组和年轻组之间任何级别的AE以及≥3级AE均无显著差异。
在接受CCRT的不可切除的III期NSCLC患者中,≥70岁的老年患者与<70岁的患者相比,PFS和AE发生率相似。然而,老年患者的OS较差。鉴于年龄是CCRT治疗效果的关键因素,应为老年患者提供更细致、谨慎的治疗方案。